Tuesday, November 24, 2009, 3:37AM AEST - The Australian Stockmarket opens in 6 hours and 23 minutes.
To create a watchlist or portfolio of shares, Register

Bristol-Myers Squibb Co. (BMY)

 3:21AM AEST: 24.69 USD  Up 0.23 (0.94%)  
 MORE ON BMY 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 BRISTOL-MYERS SQUIBB (NYSE:BMY) Delayed quote dataEdit
Last Trade:24.69 USD
Trade Time: 3:21AM AEST
Change:Up 0.23 (0.94%)
Prev Close:24.46
Open:24.56
Bid:N/A
Ask:N/A
1y Target Est:24.28
Day's Range:24.50 - 24.78
52wk Range:17.23 - 24.63
Volume:8,064,633
Avg Vol (3m):11,487,900
Market Cap:48.91B
P/E (ttm):12.77
EPS (ttm):1.93
Div & Yield:1.24 (5.07%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add BMY to Portfolio   Download Data

 HEADLINES 
•Bristol-Myers extends partnership with Asterand
AP (Tue 3:19AM)
•Rocket Stocks for the Week
at TheStreet.com (Tue 1:20AM)
•Good News for Bristol-Myers
Zacks.com (Tue 1:07AM)
•[$$] Sanofi Has Lots of Upside Catalysts
at RealMoney by TheStreet.com (Tue 12:12AM)
•[$$] Investors, Beware
at Barrons.com (Sat, Nov 21)
•UPDATE - FDA OKs Abilify for child autism irritability
at Reuters (Sat, Nov 21)
•FDA OKs Abilify for autism-linked irritability
AP (Sat, Nov 21)
•Sanofi-Aventis Falling Off a Patent Cliff?
at CNBC (Sat, Nov 21)
•U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
Business Wire (Sat, Nov 21)
•Big Pharma Mergers: Good News Or Bad?
Investor's Business Daily (Sat, Nov 21)
•[$$] Bristol-Myers Faces Lower Sales
at Barrons.com (Sat, Nov 21)
•Pozen Initiates Phase III on PA325/40
Zacks.com (Sat, Nov 21)
•AstraZeneca Seeks FDA Approval
Zacks.com (Sat, Nov 21)
•Jim Cramer's Portfolios of the Week
at TheStreet.com (Sat, Nov 21)
More Headlines for BMY...
 ANALYST 
EPS Est (next year) (Dec-09) :2.03
EPS Est (in 2 years) (Dec-10) :2.20
Avg Rec (current)*:2.5
PEG Ratio:2.06
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices